Eli Lilly Plans Oral Weight-Loss Drug Launch in Europe, UK

Eli Lilly and Company (NYSE: LLY) plans to launch its oral weight-loss drug in European and British markets in the second half of 2026 or early 2027, according to Reuters citing Executive Vice President Patrik Jonsson.

The Product

The oral drug represents a significant development in the growing obesity treatment market, offering a non-injectable alternative for patients. The company has not yet disclosed the brand name or full clinical details.

Pricing and Availability

The launch will initially target self-pay patients, without waiting for government insurance coverage approvals. This approach may accelerate market access but limits the potential user base.

Competition

Eli Lilly faces strong competition from Novo Nordisk (NVO), which markets Wegovy (injectable) and Rybelsus (oral) for weight loss. Other companies like Pfizer and Viking Therapeutics are also developing their own oral obesity drugs.

Potential Impact on the Company

This launch represents an opportunity for Eli Lilly to strengthen its position in the obesity treatment market, which could exceed $100 billion by 2030. However, success depends on the drug's efficacy and safety compared to competitors, as well as pricing and insurance coverage strategy.